Hepatotoxicity of antiretrovirals: incidence, mechanisms and management.

One of the toxicities linked to the use of antiretrovirals is the elevation of transaminases. Liver toxicity is a cause of morbidity, mortality, and treatment discontinuation in HIV-infected patients. While several antiretrovirals have been reported to cause fatal acute hepatitis, they most often cause asymptomatic elevations of transaminases. Liver toxicity is more frequent among subjects with chronic hepatitis C and/or B. The incidence of drug-induced liver toxicity is not well known for most antiretrovirals. The contribution of each particular drug to the development of hepatotoxicity in a HAART regimen is difficult to determine. Possible pathogenic mechanisms involved in hepatotoxicity are multiple, including direct drug toxicity, immune reconstitution in the presence of HCV and/or HBV co-infections, hypersensitivity reactions with liver involvement, and mitochondrial toxicity. Other pathogenic pathways may be involved, such as insulin resistance caused by several antiretrovirals, which may contribute to the development of steatohepatitis. The management of liver toxicity is based mainly on its clinical impact, severity and pathogenic mechanism.

[1]  M. Hamrell,et al.  Hepatomegaly with severe steatosis in HIV‐seropositive patients , 1993, AIDS.

[2]  M. Lederman,et al.  Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects. , 2005, The Journal of infectious diseases.

[3]  G. Gores,et al.  Drug‐induced liver injury: Mechanisms and test systems , 2001, Hepatology.

[4]  M. French,et al.  Hepatitis C virus‐associated hepatitis following treatment of HIV‐infected patients with HIV protease inhibitors: an immune restoration disease? , 1998, AIDS.

[5]  H. El‐Serag,et al.  Hepatitis C coinfection increases the risk of fulminant hepatic failure in patients with HIV in the HAART era. , 2005, Journal of hepatology.

[6]  V. Soriano,et al.  Incidence of Liver Injury After Beginning Antiretroviral Therapy with Efavirenz or Nevirapine , 2003, HIV clinical trials.

[7]  P. Morlat,et al.  Hepatitis B or Hepatitis C Virus Infection Is a Risk Factor for Severe Hepatic Cytolysis after Initiation of a Protease Inhibitor-Containing Antiretroviral Regimen in Human Immunodeficiency Virus-Infected Patients , 2000, Antimicrobial Agents and Chemotherapy.

[8]  C. Manegold,et al.  Reactivation of hepatitis B virus replication accompanied by acute hepatitis in patients receiving highly active antiretroviral therapy. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  D. Dieterich,et al.  Lack of hepatotoxicity associated with nonnucleoside reverse transcriptase inhibitors. , 2002 .

[10]  P. Price,et al.  Association of increased hepatitis C virus (HCV)-specific IgG and soluble CD26 dipeptidyl peptidase IV enzyme activity with hepatotoxicity after highly active antiretroviral therapy in human immunodeficiency virus-HCV-coinfected patients. , 2002, The Journal of infectious diseases.

[11]  U. Walker,et al.  Increased long-term mitochondrial toxicity in combinations of nucleoside analogue reverse-transcriptase inhibitors , 2002, AIDS.

[12]  Rolf Hilfiker,et al.  The use of single-nucleotide polymorphism maps in pharmacogenomics , 2000, Nature Biotechnology.

[13]  M. Leist,et al.  Cytokine-mediated hepatic apoptosis. , 1998, Reviews of physiology, biochemistry and pharmacology.

[14]  Vijayabhaskar R. Kandula,et al.  Tipranavir: a novel second-generation nonpeptidic protease inhibitor , 2005, Expert review of anti-infective therapy.

[15]  K. Anastos,et al.  Longitudinal effect of antiretroviral therapy on markers of hepatic toxicity: impact of hepatitis C coinfection. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[16]  R. Chaisson,et al.  Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. , 2000, JAMA.

[17]  R. Green,et al.  Mechanism of indinavir-induced hyperbilirubinemia , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[18]  V. Soriano,et al.  Short communication: liver toxicity of lopinavir-containing regimens in HIV-infected patients with or without hepatitis C coinfection. , 2004, AIDS research and human retroviruses.

[19]  P. Couzigou,et al.  Severe hepatic cytolysis: incidence and risk factors in patients treated by antiretroviral combinations. Aquitaine Cohort, France, 1996-1998. Groupe dEpidémiologie Clinique de Sida en Aquitaine (GECSA). , 1999, AIDS.

[20]  J. Smeitink,et al.  Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway , 1998, AIDS.

[21]  D. Cooper,et al.  Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: acohort study , 1999, The Lancet.

[22]  J. Macías,et al.  Effect of antiretroviral drugs on liver fibrosis in HIV-infected patients with chronic hepatitis C: harmful impact of nevirapine , 2004, AIDS.

[23]  J. Angel,et al.  Hepatotoxicity associated with antiretroviral therapy containing dual versus single protease inhibitors in individuals coinfected with hepatitis C virus and human immunodeficiency virus. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[24]  C. Flexner.  HIV-protease inhibitors. , 1998, The New England journal of medicine.

[25]  Dorothy Bray,et al.  Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial , 1999, The Lancet.

[26]  C. Dreezen,et al.  Risk factors for hepatotoxicity in HIV-1-infected patients receiving ritonavir and saquinavir with or without stavudine. Prometheus Study Group. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[27]  J. Beijnen,et al.  Hepatotoxicity following nevirapine-containing regimens in HIV-1-infected individuals. , 2002, Pharmacological research.

[28]  P. Reiss,et al.  Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection , 2000, AIDS.

[29]  T. Cihlar,et al.  Assessment of Mitochondrial Toxicity in Human Cells Treated with Tenofovir: Comparison with Other Nucleoside Reverse Transcriptase Inhibitors , 2002, Antimicrobial Agents and Chemotherapy.

[30]  B. Hirschel,et al.  Impact of treatment with human immunodeficiency virus (HIV) protease inhibitors on hepatitis C viremia in patients coinfected with HIV. , 1998, The Journal of infectious diseases.

[31]  V. Soriano,et al.  Risk factors for severe hepatic injury after introduction of highly active antiretroviral therapy. , 2001 .

[32]  V. Soriano,et al.  Role of Hepatitis C Virus Genotype in the Development of Severe Transaminase Elevation After the Introduction of Antiretroviral Therapy , 2002, Journal of acquired immune deficiency syndromes.

[33]  J. Lisziewicz,et al.  Direct analysis of mitochondrial toxicity of antiretroviral drugs , 2001, AIDS.

[34]  Andrew Phillips,et al.  Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy , 2001, AIDS.

[35]  Geoffrey Scott,et al.  Prophylaxis with a nevirapine-containing triple regimen after exposure to HIV-1 , 2001, The Lancet.

[36]  R. Chung,et al.  IMMUNE RECOVERY IS ASSOCIATED WITH PERSISTENT RISE IN HEPATITIS C VIRUS RNA, INFREQUENT LIVER TEST FLARES, AND IS NOT IMPAIRED BY HEPATITIS C VIRUS IN CO-INFECTED SUBJECTS , 2002, AIDS.

[37]  G. Cláudio,et al.  DRESS syndrome associated with nevirapine therapy. , 2001, Archives of internal medicine.

[38]  Stuart Johnson,et al.  Hepatotoxicity after prophylaxis with a nevirapine-containing antiretroviral regimen. , 2002, Annals of internal medicine.

[39]  S. Knowles,et al.  Idiosyncratic drug reactions: the reactive metabolite syndromes , 2000, The Lancet.

[40]  P. Duca,et al.  Lopinavir/ritonavir treatment in HIV antiretroviral‐experienced patients: evaluation of risk factors for liver enzyme elevation , 2004, HIV medicine.

[41]  C. Quereda,et al.  Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C virus coinfection. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[42]  M. Moroni,et al.  Low frequency of severe hepatotoxicity and association with HCV coinfection in HIV-positive patients treated with HAART. , 2001 .

[43]  M. Sulkowski.  Hepatotoxicity Associated with Antiretroviral Therapy Containing HIV-1 Protease Inhibitors , 2003, Seminars in liver disease.

[44]  S. Lawson-Ayayi,et al.  A cohort study of nevirapine tolerance in clinical practice: French Aquitaine Cohort, 1997-1999. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[45]  J. Roujeau,et al.  Hypersensitivity syndrome associated with zalcitabine therapy , 1996, The Lancet.

[46]  B. Portmann,et al.  Acute liver failure associated with antiretroviral treatment for HIV: a report of six cases. , 2002, Journal of hepatology.

[47]  D. Mayers,et al.  A Comprehensive Hepatic Safety Analysis of Nevirapine in Different Populations of HIV Infected Patients* , 2003, Journal of acquired immune deficiency syndromes.

[48]  R. Chaisson,et al.  Hepatotoxicity associated with nevirapine or efavirenz‐containing antiretroviral therapy: Role of hepatitis C and B infections , 2002, Hepatology.

[49]  V. Soriano,et al.  Hepatotoxicity after introduction of highly active antiretroviral therapy. , 1998, AIDS.

[50]  C. Moore,et al.  Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts , 2005, AIDS.

[51]  V. Vullo,et al.  Acute clinical hepatitis in an HIV-seropositive hepatitis B carrier receiving protease inhibitor therapy. , 1998, AIDS.

[52]  N. Foudraine,et al.  Clinical features and risk factors of lactic acidosis following long-term antiretroviral therapy: 4 fatal cases , 2000, International journal of STD & AIDS.

[53]  T. Ferraro,et al.  Enhancement of hepatitis C virus replication and liver damage in HIV-coinfected patients on antiretroviral combination therapy. , 1998, AIDS.

[54]  R. Hewitt.  Abacavir hypersensitivity reaction. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[55]  M. Johnson,et al.  Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures , 2005, AIDS.

[56]  V. Soriano,et al.  Care of patients with chronic hepatitis B and HIV co-infection: recommendations from an HIV-HBV International Panel. , 2002, AIDS.

[57]  G. D'offizi,et al.  Liver enzyme elevation in hepatitis C virus (HCV)-HIV-coinfected patients prior to and after initiating HAART: role of HCV genotypes. , 2006, AIDS research and human retroviruses.

[58]  M. Bonacini,et al.  Jaundice and hepatocellular damage associated with nevirapine therapy. , 2001 .

[59]  P. Morand,et al.  Change in transaminases in hepatitis C virus- and HIV-coinfected patients after highly active antiretroviral therapy: differences between complete and partial virologic responders? , 2000, AIDS research and human retroviruses.

[60]  D. Dieterich,et al.  Hepatotoxicity of antiretroviral therapy. , 2003, AIDS reviews.

[61]  R. Byers,et al.  Trends in diseases reported on U.S. death certificates that mentioned HIV infection, 1987-1999. , 2002 .

[62]  J. Stern,et al.  A near-fatal hypersensitivity reaction to abacavir: case report and literature review. , 2001, The AIDS reader.

[63]  B. Gazzard,et al.  Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study , 2004, The Lancet.

[64]  M. Chevallier,et al.  Fulminant hepatitis with severe lactate acidosis in HIV‐infected patients on didanosine therapy , 1994, Journal of internal medicine.

[65]  M. Nahata,et al.  Acute Hepatitis and Bleeding Possibly Induced by Zidovudine and Ritonavir in an Infant with HIV Infection , 2000, Pharmacotherapy.

[66]  Richard D Moore,et al.  Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir , 2004, AIDS.

[67]  F. Wit,et al.  Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy. , 2002, The Journal of infectious diseases.

[68]  J. Peña,et al.  Acute hepatitis in HIV-infected patients during ritonavir treatment. , 1998, AIDS.

[69]  D. Snydman,et al.  Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[70]  M. Sulkowski.  Drug-induced liver injury associated with antiretroviral therapy that includes HIV-1 protease inhibitors. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[71]  V. Johnson,et al.  Symptomatic lactic acidosis in hospitalized antiretroviral-treated patients with human immunodeficiency virus infection: a report of 12 cases. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[72]  F. Callea,et al.  Severe Hepatotoxicity During Combination Antiretroviral Treatment: Incidence, Liver Histology, and Outcome , 2003, Journal of acquired immune deficiency syndromes.

[73]  A. Aceti,et al.  Hepatotoxicity Development During Antiretroviral Therapy Containing Protease Inhibitors in Patients With HIV: The Role of Hepatitis B and C Virus Infection , 2002, Journal of acquired immune deficiency syndromes.